Mor Research Applications Ltd.

Ayala Pollack

Zeev Dvashi

This disclosure relates to compositions for use in treatment of Alzheimer's Disease, and/or a ocular and retinal degenerative disease, such as age related macular degeneration. The described compositions include effective amounts of LLMe, the hydrobromide form thereof, or functional derivatives thereof. Methods of treatment of a retinal degenerative disease of Alzheimer's Disease using the described compositions are also provided.

Compositions and methods for treatment of retinal degenerative diseases

Disclosed herein are methods for treatment for fibrosis, ocular pathologies associated with fibrosis, including proliferative vitreoretinopathy (PVR) by inhibiting the activity of activated transforming growth factor &#x3b2; activated kinase 1 (TAK1), or activation thereof. Pharmaceutical compositions for use in the described treatments are also provided.

Treatments for fibrotic diseases

This disclosure relates to compositions for use in treatment of a retinal degenerative disease, such as age related macular degeneration. The described compositions include agents for activating p38 and/or JNK signaling through the activation of TAK1 in the retinal pigment epithelium of a subject diagnosed with the disease. Methods of treatment of a retinal degenerative disease using the described compositions are also provided.

Growing community of inventors

Tel Aviv, Israel

Ayala Pollack